- Home
- BTAI vs MEGL Comparison
BTAI vs MEGL Comparison
Compare BTAI & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MEGL
- Stock Information
- Founded
- BTAI 2017
- MEGL 2016
- Country
- BTAI United States
- MEGL Hong Kong
- Employees
- BTAI N/A
- MEGL N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MEGL Finance: Consumer Services
- Sector
- BTAI Health Care
- MEGL Finance
- Exchange
- BTAI Nasdaq
- MEGL Nasdaq
- Market Cap
- BTAI 8.3M
- MEGL 6.8M
- IPO Year
- BTAI 2018
- MEGL 2022
- Fundamental
- Price
- BTAI $5.48
- MEGL $1.43
- Analyst Decision
- BTAI Strong Buy
- MEGL
- Analyst Count
- BTAI 4
- MEGL 0
- Target Price
- BTAI $40.00
- MEGL N/A
- AVG Volume (30 Days)
- BTAI 22.4M
- MEGL 139.2K
- Earning Date
- BTAI 08-12-2025
- MEGL 08-26-2025
- Dividend Yield
- BTAI N/A
- MEGL N/A
- EPS Growth
- BTAI N/A
- MEGL N/A
- EPS
- BTAI N/A
- MEGL N/A
- Revenue
- BTAI $868,000.00
- MEGL $1,645,862.00
- Revenue This Year
- BTAI N/A
- MEGL N/A
- Revenue Next Year
- BTAI $328.13
- MEGL N/A
- P/E Ratio
- BTAI N/A
- MEGL N/A
- Revenue Growth
- BTAI N/A
- MEGL N/A
- 52 Week Low
- BTAI $1.17
- MEGL $1.02
- 52 Week High
- BTAI $13.36
- MEGL $5.52
- Technical
- Relative Strength Index (RSI)
- BTAI 67.45
- MEGL 46.93
- Support Level
- BTAI $1.30
- MEGL $1.32
- Resistance Level
- BTAI $8.08
- MEGL $1.50
- Average True Range (ATR)
- BTAI 1.23
- MEGL 0.09
- MACD
- BTAI 0.33
- MEGL 0.00
- Stochastic Oscillator
- BTAI 61.65
- MEGL 26.89
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.